Fresh analysis indicates that individuals who come off new weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who end traditional diet and exercise programs.
Findings released in a major health publication shows that while obese people often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"People buying such medications should be aware of the potential of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about a year and a half.
Analyzing Treatments
The study, which examined dozens of studies involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
The team point out that people who shed pounds through diet and exercise usually see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Fast Regain
Experts believe the way of the jabs explains the accelerated weight return.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in appetite is no longer kept in check, making binge eating far more likely."
A Lifelong Disease?
The NHS suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the likelihood of weight regain, the therapy is often long-term.
This perspective is supported by drug manufacturers, who state that the results "highlight the persistent character of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Individuals who have come off the medication explain a powerful resurgence of hunger.
"It was like a switch flipping and I was suddenly ravenous," recalled one woman.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural changes during therapy.
Significant Use
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers caution that while the jabs are potent tools for weight loss, they are not a magic cure and maintained weight loss hinges on integrated lifestyle support.